Top

Published in:

01-12-2021 | Metastasis | Research

The mechanisms of colorectal cancer cell mesenchymal-epithelial transition induced by hepatocyte exosome-derived miR-203a-3p

Authors: Heyang Xu, Qiusheng Lan, Yongliang Huang, Yang Zhang, Yujie Zeng, Pengwei Su, Ziqiang Chu, Wei Lai, Zhonghua Chu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Liver metastasis is the most common cause of death in patients with colorectal cancer (CRC). Phosphatase of regenerating liver-3 induces CRC metastasis by epithelial-to-mesenchymal transition, which promotes CRC cell liver metastasis. Mesenchymal-to-epithelial transition (MET), the opposite of epithelial-to-mesenchymal transition, has been proposed as a mechanism for the establishment of metastatic neoplasms. However, the molecular mechanism of MET remains unclear.

Methods

Using Immunohistochemistry, western blotting, invasion assays, real-time quantitative PCR, chromatin immunoprecipitation, luciferase reporter assays, human miRNA arrays, and xenograft mouse model, we determined the role of hepatocyte exosome-derived miR-203a-3p in CRC MET.

Results

In our study, we found that miR-203a-3p derived from hepatocyte exosomes increased colorectal cancer cells E-cadherin expression, inhibited Src expression, and reduced activity. In this way miR-203a-3p induced the decreased invasion rate of CRC cells.

Coclusion

MiR-203a-3p derived from hepatocyte exosomes plays an important role of CRC cells to colonize in liver.

Hashimoto M, Kobayashi T, Tashiro H, Arihiro K, Kikuchi A. Ohdan H, h-prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases. Int J Cancer. 2016;139(4):812–23. https://doi.org/10.1002/ijc.30118.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62(1):10–29. https://doi.org/10.3322/caac.20138.CrossRefPubMed

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64. https://doi.org/10.1126/science.1203543.CrossRefPubMed

Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96. https://doi.org/10.1038/nrm3758.CrossRefPubMedPubMedCentral

Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem. 2015;280:8094–100.CrossRef

Bae GY, Choi SJ, Lee JS, Jo J, Lee J, Kim J, et al. Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget. 2013;4(12):2512–22. https://doi.org/10.18632/oncotarget.1463.CrossRefPubMedPubMedCentral

Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein tyrosine phosphatases in the human genome. CELL. 2004;117(6):699–711. https://doi.org/10.1016/j.cell.2004.05.018.CrossRefPubMed

Saha S. A phosphatase associated with metastasis of colorectal Cancer. Science. 2001;294(5545):1343–6. https://doi.org/10.1126/science.1065817.CrossRefPubMed

Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 Down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67(7):2922–6. https://doi.org/10.1158/0008-5472.CAN-06-3598.CrossRefPubMed

10.

Liu Y, Zhou J, Chen J, Gao W, Le Y, Ding Y, et al. PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly. Cancer Biol Ther. 2009;8(14):1352–9. https://doi.org/10.4161/cbt.8.14.8695.CrossRefPubMed

11.

Hu L, Luo H, Wang W, Li H, He T. Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis. PLoS One. 2013;8(10):e76927. https://doi.org/10.1371/journal.pone.0076927.CrossRefPubMedPubMedCentral

12.

Liu H, Al-aidaroos AQ, Wang H, Guo K, Li J, Zhang HF, et al. PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells. BMC Cancer. 2013;13(1):80. https://doi.org/10.1186/1471-2407-13-80.CrossRefPubMedPubMedCentral

13.

Zhang J, Xiao Z, Lai D, Sun J, He C, Chu Z. Ye H, et al, miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer. 2012;107(2):352–9. https://doi.org/10.1038/bjc.2012.251.CrossRefPubMedPubMedCentral

14.

Lai W, Liu L, Zeng Y, Wu H, Xu H, Chen S, et al. KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer. Med Oncol. 2013;30(2):566. https://doi.org/10.1007/s12032-013-0566-z.CrossRefPubMed

15.

Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, et al. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest. 2013;123(8):3459–71. https://doi.org/10.1172/JCI66824.CrossRefPubMedPubMedCentral

16.

Epstein DM, Buck E. Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function. J Clin Invest. 2014;125:4320–2.CrossRef

17.

De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17–27. https://doi.org/10.1517/14728222.2011.639361.CrossRefPubMed

18.

Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, et al. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015;26(8):1710–4. https://doi.org/10.1093/annonc/mdv176.CrossRefPubMed

19.

Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell. 2012;151(5):937–50. https://doi.org/10.1016/j.cell.2012.10.035.CrossRefPubMedPubMedCentral

20.

Yates CC, Shepard CR, Stolz DB, Wells A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer. 2011;96:1246–52.CrossRef

21.

Harding CV, Heuser JE, Stahl PD. Exosomes: looking back three decades and into the future. J Cell Biol. 2013;200(4):367–71. https://doi.org/10.1083/jcb.201212113.CrossRefPubMedPubMedCentral

22.

Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–21. https://doi.org/10.1016/j.ccell.2014.09.005.CrossRefPubMedPubMedCentral

23.

Shin VY, Chu K-M. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20(30):10432–9.CrossRefPubMedPubMedCentral

24.

He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31. https://doi.org/10.1038/nrg1379.CrossRefPubMed

25.

Yang Y, Li X, Du J, Yin Y, Li Y. Involvement of microRNAs-MMPs-E-cadherin in the migration and invasion of gastric cancer cells infected with helicobacter pylori. Exp Cell Res. 2018;367(2):196–204. https://doi.org/10.1016/j.yexcr.2018.03.036.CrossRefPubMed

26.

Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248–54. https://doi.org/10.1016/0003-2697(76)90527-3.CrossRefPubMed

27.

Lai W, Chen S, Wu H, Guan Y, Liu L, Zeng Y, et al. PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels. Oncol Rep. 2011;26(4):909–17. https://doi.org/10.3892/or.2011.1366.CrossRefPubMed

28.

Vu T, Datta PK. Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers (Basel). 2017;9(12):171

29.

Maejima Y, Ueba H, Kuroki M, Yasu T, Hashimoto S, Nabata A, et al. Src family kinases and nitric oxide production are required for hepatocyte growth factor-stimulated endothelial cell growth. Atherosclerosis. 2003;167(1):89–95. https://doi.org/10.1016/S0021-9150(02)00384-2.CrossRefPubMed

30.

Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54. https://doi.org/10.1038/nrc822.CrossRefPubMed

31.

Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol. 2013;1(1):3–11. https://doi.org/10.3892/mco.2012.28.CrossRefPubMed

32.

Peng L, Jin G, Wang L, Guo J, Meng L, Shou C. Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. Biochem Biophys Res Commun. 2006;342(1):179–83. https://doi.org/10.1016/j.bbrc.2006.01.102.CrossRefPubMed

33.

Forte E, Orsatti L, Talamo F, Barbato G, De Francesco R, Tomei L. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta. 1783;2008:334–44.

34.

Sung BH, Ketova T, Hoshino D, Zijlstra A, Weaver AM. Directional cell movement through tissues is controlled by exosome secretion. Nat Commun. 2005;6:7164.CrossRef

35.

Kawikova I, Askenase PW. Diagnostic and therapeutic potentials of exosomes in CNS diseases. Brain Res. 2014;1617:63–71. https://doi.org/10.1016/j.brainres.2014.09.070.CrossRefPubMedPubMedCentral

36.

Huo W, Du M, Pan X, Zhu X, Gao Y, Li Z. MiR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. FEBS Open Bio. 2017 Aug;7(8):1085–91. https://doi.org/10.1002/2211-5463.12248.CrossRefPubMedPubMedCentral

37.

Hou Y, Hu Q, Huang J, Xiong H. Omeprazole inhibits cell proliferation and induces G0/G1 cell cycle arrest through up-regulating miR-203a-3p expression in Barrett's esophagus cells. Front Pharmacol. 2017;8:968.CrossRefPubMed

38.

Lin C, Gao H, Liang J, et al. MiR-203a-3p promotes colorectal cancer proliferation and migration by targeting PDE4D. Am J Cancer Res. 2018;8(12):2387–401.

39.

Falcone G, Felsani A, D'Agnano I. Signaling by exosomal microRNAs in cancer. J Exp Clin Cancer Res. 2015;34(1):32. https://doi.org/10.1186/s13046-015-0148-3.CrossRefPubMedPubMedCentral

40.

Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13(1):513–609. https://doi.org/10.1146/annurev.cellbio.13.1.513.CrossRefPubMed

41.

Rivard N. Phosphatidylinositol 3-kinase: a key regulator in adherens junction formation and function. Front Biosci (Landmark Ed). 2009;14:510–22.CrossRef

42.

Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004;23(48):7957–68. https://doi.org/10.1038/sj.onc.1208079.CrossRefPubMed

43.

Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16(1):102–8. https://doi.org/10.1093/annonc/mdi006.CrossRefPubMed

Title: The mechanisms of colorectal cancer cell mesenchymal-epithelial transition induced by hepatocyte exosome-derived miR-203a-3p
Authors: Heyang Xu
Qiusheng Lan
Yongliang Huang
Yang Zhang
Yujie Zeng
Pengwei Su
Ziqiang Chu
Wei Lai
Zhonghua Chu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08419-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Coclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The quality of life in women with cervical cancer and precancerous lesions of Han and ethnic minorities in Southwest China

Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

The effect of hypoxia on PD-L1 expression in bladder cancer

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer